Zentalis Pharmaceuticals, Inc. Increase (Decrease) in Accounts Receivable
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Increase (Decrease) in Accounts Receivable of -$5.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was $4.00K.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-12-31 was -$104.00K, a 135.25% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for the quarter ending 2021-09-30 was $103.00K, a 110.20% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$5.00M, a 200.00% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $5.00M.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$5.00M 10-K · filed 2026-03-26 | |||
| 2024-12-31 | $5.00M 10-K · filed 2026-03-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-26 | |||
| 2022-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $0.00 10-K · filed 2025-03-26 | ||
| 2022-09-30 | -$4.00K 10-Q · filed 2022-11-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | -$104.00K derived: sum of 2 quarters · filed 2022-05-05 | -$1.00K derived: sum of 3 quarters · filed 2022-11-09 | -$244.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.00K derived: sum of 2 quarters · filed 2022-11-09 | -$244.00K derived: sum of 3 quarters · filed 2022-11-09 | -$413.00K 10-K · filed 2022-02-24 |
| 2021-09-30 | $103.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$140.00K derived: sum of 2 quarters · filed 2022-11-09 | -$309.00K 10-Q · filed 2022-11-09 | -$14.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$412.00K 10-Q · filed 2021-08-12 | -$117.00K derived: sum of 3 quarters · filed 2022-05-05 | -$68.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | -$169.00K 10-Q · filed 2022-05-05 | $126.00K derived: sum of 2 quarters · filed 2022-05-05 | $175.00K derived: sum of 3 quarters · filed 2022-05-05 | $109.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $344.00K derived: sum of 2 quarters · filed 2022-02-24 | $278.00K derived: sum of 3 quarters · filed 2022-02-24 | $277.00K 10-K · filed 2022-02-24 |
| 2020-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$17.00K derived: sum of 2 quarters · filed 2021-11-10 | -$18.00K 10-Q · filed 2021-11-10 | $72.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$67.00K 10-Q · filed 2021-08-12 | $23.00K derived: sum of 3 quarters · filed 2022-02-24 | -$247.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$1.00K 10-Q · filed 2021-05-17 | $89.00K derived: sum of 2 quarters · filed 2022-02-24 | -$181.00K derived: sum of 3 quarters · filed 2022-02-24 | -$553.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$180.00K derived: sum of 2 quarters · filed 2022-02-24 | -$552.00K derived: sum of 3 quarters · filed 2022-02-24 | -$777.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | -$270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$642.00K derived: sum of 2 quarters · filed 2020-11-09 | -$867.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | -$372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$597.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$225.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |